With a median follow up of 3.78 years for GSE32603 and 2.74 years for GSE25066, we found a significantly lower risk of tumor recurrence in patients with high expression of ALDH3A2 in the primary tumor compared with those having tumors with low expression of ALDH3A2 in both databases (Figure 7). The gene discussed is ALDH3A2; the disease is neoplasm.